Drug Profile
Research programme: cancer therapeutics - Arch BioPartners/University of Colorado
Alternative Names: GH501aLatest Information Update: 10 Jul 2016
Price :
$50
*
At a glance
- Originator University of Colorado Foundation
- Developer Arch Biopartners; University of Colorado Foundation
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 09 Sep 2011 A lead compound, GH 501a, is selected for further development